Kenvue/$KVUE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
- Ticker
- $KVUE
- Sector
- Consumer Essentials
- Primary listing
- NYSE
- Employees
- 21,890
- Headquarters
- Summit, United States
- Website
- www.kenvue.com
Kenvue Metrics
BasicAdvanced
$37B
21.94
$0.88
0.45
$1.04
4.35%
Price and volume
Market cap
$37B
Beta
0.45
52-week high
$20.13
52-week low
$15.88
Average daily volume
20M
Dividend rate
$1.04
Financial strength
Current ratio
0.955
Quick ratio
0.57
Long term debt to equity
0.706
Total debt to equity
0.821
Dividend payout ratio (TTM)
94.50%
Interest coverage (TTM)
7.19%
Profitability
EBITDA (TTM)
3,504
Gross margin (TTM)
58.53%
Net profit margin (TTM)
10.88%
Operating margin (TTM)
19.54%
Effective tax rate (TTM)
26.71%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
7.03%
Return on equity (TTM)
16.25%
Valuation
Price to earnings (TTM)
21.943
Price to revenue (TTM)
2.385
Price to book
3.65
Price to tangible book (TTM)
-5
Price to free cash flow (TTM)
15.845
Free cash flow yield (TTM)
6.31%
Free cash flow per share (TTM)
1.219
Dividend yield (TTM)
5.40%
Forward dividend yield
4.35%
Growth
Revenue change (TTM)
3.49%
Earnings per share change (TTM)
17.69%
3-year revenue growth (CAGR)
-0.03%
3-year earnings per share growth (CAGR)
-2.23%
3-year dividend per share growth (CAGR)
60.86%
What the Analysts think about Kenvue
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Analyst projections of the future price of Kenvue stock.
Bulls say / Bears say
The EU’s conditional approval clears a major hurdle for Kimberly-Clark’s planned fourth-quarter acquisition, improving the prospect that Kenvue shareholders will receive the agreed deal consideration on schedule. (The Wall Street Journal, Kenvue)
Kenvue reported a third consecutive quarter of organic sales growth, with gains across its segments and improving Tylenol trends in the US. That suggests its brand-building efforts are beginning to support a recovery. (Kenvue)
The FDA approved Tylenol with naproxen, a new over-the-counter pain-relief combination with three years of exclusivity. Its launch gives Kenvue a fresh product opportunity in a core category. (Kenvue)
A US appeals court revived more than 500 lawsuits alleging a link between Tylenol use and autism. The cases remain unresolved, but they create legal and reputational risk for one of Kenvue’s best-known brands. (Reuters)
Inflation, tariffs and currency costs pushed Kenvue’s second-quarter adjusted gross margin down to 60.2% from 60.9% a year earlier. Continued cost pressure could limit profit growth even if sales improve. (Reuters)
The sales recovery remains modest: second-quarter organic sales grew 1.6%, and revenue narrowly missed analysts’ estimates. Self Care organic sales rose only 0.6%, with volume declining, so growth in key categories is not yet broad or strong. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Kenvue Financial Performance
Revenues and expenses
Kenvue Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kenvue News
AllArticlesVideos
Funds containing Kenvue
AllUSDEURGBP
Fund name | Fund size | $KVUE weighting |
|---|---|---|
SPDR S&P US Dividend Aristocrats€SPYD | $3.8B | 1.41% |
SPDR S&P US Dividend Aristocrats£USDV | $3.8B | 1.41% |
Xtrackers MSCI World Consumer Staples£XWCS | $926M | 0.76% |
Xtrackers MSCI World Consumer Staples$XDWS | $926M | 0.76% |
SPDR MSCI World Consumer Staples$WCOS | $157M | 0.76% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.